Roboligent

Cover Block

PUBLIC

Attribute	Details
Company	Roboligent
Tagline	AI-powered mobile manipulator robots for manufacturing and healthcare, focusing on human-robot interaction and automation.
Headquarters	Austin, USA
Founded	2016
Stage	Seed
Business Model	Hardware + Software
Industry	Deeptech
Technology	Robotics
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Seed (total disclosed ~$1,110,000)

Links

PUBLIC

• Website: https://www.roboligent.com
• LinkedIn: https://www.linkedin.com/company/roboligent

Executive Summary

PUBLIC

Roboligent is a Texas-based robotics company developing AI-powered mobile manipulator robots designed to work safely alongside humans, a proposition that merits investor attention due to its focus on solving acute labor shortages in both healthcare and manufacturing through a single, versatile force-control technology [Roboligent website]. Founded in 2016 as LinkDyn Robotics, the company initially targeted automated physical therapy before expanding its platform to address industrial tasks like warehousing and assembly [CB Insights]. Its core differentiation lies in a proprietary force-controlled, or "soft," robotics system that enables safe human-robot interaction, which is commercialized through two main products: the ROBIN mobile dual-arm humanoid for industrial automation and the REGEN (Optimo Regen) robot for clinical rehabilitation [Roboligent website, June 2024].

Founder and CEO Bongsu Kim holds a Ph.D. in Robotics from the University of Texas at Austin, grounding the company's technical roadmap in academic research [Crunchbase]. To date, Roboligent has raised approximately $1.11 million in a mix of equity and non-dilutive grants from a consortium that includes Goseong Engineering, AFWERX, and the National Science Foundation, indicating early validation from both strategic and government sources [CB Insights]. The business model combines hardware sales with software for task management, targeting high-value automation in sectors where precision and safety are paramount. Over the next 12-18 months, the key indicators to monitor are the progression of announced proof-of-concept projects for ROBIN into paid commercial deployments and the establishment of named healthcare partners for the REGEN system, which would signal tangible market traction beyond the research and development phase.

Data Accuracy: YELLOW -- Core company facts are confirmed by the corporate website and Crunchbase; funding totals are reported by a single source (CB Insights) with some variance.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	Hardware + Software
Industry / Vertical	Deeptech
Technology Type	Robotics
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Seed (total disclosed ~$1,110,000)

Company Overview

PUBLIC

Roboligent operates as a lean, founder-led robotics venture from Austin, Texas, having navigated a decade-long development arc from academic research to a dual-market commercial focus. The company was incorporated in 2016 under the name LinkDyn Robotics, a detail corroborated by its corporate history on both Crunchbase and CB Insights [Crunchbase], [CB Insights]. This timeline suggests a long gestation period, typical for deep-tech hardware startups, where the initial years were likely dedicated to core technology development and securing non-dilutive grant funding.

The founder, Bongsu Kim, holds a Ph.D. in Robotics from the University of Texas at Austin, with prior graduate research completed at KAIST [Crunchbase]. His academic background in mechanical engineering and robotics provides the technical foundation for the company's focus on force-controlled manipulation. A key operational milestone was the 2024 corporate minority investment led by Goseong Engineering, which marked a shift from primarily grant-based funding to include strategic corporate capital [CB Insights]. The company's public identity and product branding also evolved during this period, culminating in the launch of its flagship platforms, ROBIN and REGEN, as detailed on its corporate website [Roboligent website].

Headcount remains small, with third-party estimates pointing to a team of approximately five employees [Explorium]. The available LinkedIn profiles confirm a handful of technical and operational roles, including a Head of Operations and a Robotics AI/ML Engineer, indicating a focused engineering team structure [LinkedIn, retrieved 2026]. The absence of a broad public footprint in terms of customer announcements or large-scale partnerships aligns with a company still in the proof-of-concept and early commercialization phase.

Data Accuracy: YELLOW -- Core facts like founding year, founder background, and recent funding are confirmed by multiple sources, but specific operational milestones and team size are based on limited public corroboration.

Product and Technology

MIXED Roboligent’s product strategy is built on a single, versatile hardware and software platform, deployed across two distinct application suites. The company’s core technology is a mobile manipulator robot, branded as ROBIN, which serves as the physical base for both industrial and healthcare automation [Roboligent website]. The platform’s defining characteristic is its focus on compliant, force-controlled robotic arms, a technology often described as “soft robotics” that is designed for safe physical interaction with human workers and patients [Roboligent website]. This force-control capability, combined with an autonomous mobile base, imitation-learning software for task acquisition, and fleet management tools, forms the technical foundation for all current products [Roboligent website].

The company has commercialized this platform in two primary directions. For industrial and logistics settings, ROBIN is positioned as a general-purpose mobile manipulator. The company cites potential applications in warehousing, retail, surface finishing, and advanced assembly, where the robot’s ability to navigate spaces and perform precise, compliant manipulation tasks could address labor shortages [CB Insights]. For healthcare, the platform is adapted into a specialized medical device called REGEN, also referred to as Optimo Regen. This product is designed to automate physical therapy exercises for patients with musculoskeletal issues, aiming to increase clinical efficiency by providing consistent, data-driven rehabilitation sessions [Roboligent website, Explorium].

Public details on the technical stack are limited to high-level descriptions from the company’s materials. The system integrates mobile navigation, dual-arm manipulation, and AI for task learning. The software layer appears to support teleoperation, allowing users to remotely control the robot for complex or hazardous tasks [Roboligent website]. The company has stated that ROBIN is currently undergoing proof-of-concept projects in various domestic and international settings, though specific partners or locations are not named [Roboligent website]. No public roadmap for future hardware iterations or software modules has been announced.

Data Accuracy: YELLOW -- Product claims are sourced directly from the company website and third-party aggregators, but detailed technical specifications and independent performance validations are not publicly available.

Market Research

PUBLIC

Roboligent's dual-market strategy targets two sectors where automation is not just an efficiency play but a response to structural labor shortages and rising quality-of-care standards.

The company's primary wedge appears to be in robotic-assisted rehabilitation, a niche within the broader medical robotics market. While no specific TAM for automated physical therapy is cited, the broader medical robotics market is a relevant analog. According to a 2024 report from Grand View Research, the global medical robotics market was valued at $12.1 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 17.5% from 2024 to 2030 [Grand View Research, 2024]. This growth is driven by an aging global population, increasing prevalence of chronic and musculoskeletal conditions, and a push to improve clinical efficiency. Roboligent's REGEN/Optimo Regen product is positioned within this trend, aiming to automate repetitive physical therapy exercises.

For its industrial applications, Roboligent targets logistics, warehousing, and advanced assembly. The global market for collaborative robots (cobots) and mobile manipulators offers another sizing reference. The International Federation of Robotics reported that shipments of collaborative robots grew by 15% in 2023, with strong demand in electronics and automotive assembly [International Federation of Robotics, 2024]. The demand driver here is the persistent labor gap in manufacturing and logistics, compounded by the need for more flexible, re-deployable automation that can work alongside human staff without extensive safety caging.

Key adjacent markets include teleoperation systems for hazardous environments and general-purpose humanoid robotics, both of which are seeing increased venture investment. The company's focus on force-controlled (soft) robotics for safe interaction is a technical differentiator that aligns with regulatory trends pushing for stricter safety standards in human-robot collaboration, particularly in the EU and North America. A macro force supporting both healthcare and industrial segments is the continued availability of non-dilutive funding from entities like the U.S. National Science Foundation and AFWERX, which Roboligent has tapped [CB Insights].

Metric	Value
Medical Robotics Market (2023)	12.1 $B
Projected CAGR (2024-2030)	17.5 %
Collaborative Robot Shipment Growth (2023)	15 %

The cited growth rates for the analogous markets underscore the tailwinds Roboligent is attempting to harness. However, the company's specific serviceable obtainable market (SOM) remains unquantified in public materials, hinging on its ability to secure initial clinical and industrial deployments for its proof-of-concept projects.

Data Accuracy: YELLOW -- Market sizing is based on analogous, third-party industry reports. Roboligent's specific target segment sizes are not publicly confirmed.

Competitive Landscape

MIXED Roboligent operates at the intersection of two distinct but overlapping competitive arenas: specialized medical rehabilitation robots and general-purpose mobile manipulators for industrial settings.

Given the absence of named competitors in the structured research, the analysis proceeds without a formal comparison table. The competitive map is defined by application rather than direct product-for-product rivals.

In medical rehabilitation, the competitive set includes large incumbent medical device manufacturers with established sales channels and regulatory expertise, such as Hocoma (a DIH International company) with its Lokomat and Armeo systems, and smaller innovators like Ekso Bionics. These companies offer task-specific, clinically validated devices. Roboligent's REGEN/Optimo Regen, by contrast, is positioned as a more versatile, force-controlled platform for automating a range of physical therapy exercises [Roboligent website, "REGEN"]. The defensible edge here is the proprietary force-control (soft robot) technology enabling safe human interaction, a technical moat built on the founder's doctoral research. This edge is durable if protected by patents and clinical validation data, but perishable if larger incumbents develop or acquire similar compliant actuation technology. The company's most significant exposure in this segment is the lengthy and capital-intensive FDA clearance pathway for medical devices, a process where well-funded incumbents have a structural advantage.

The industrial and logistics segment pits Roboligent's ROBIN platform against a different class of competitors. These include established collaborative robot (cobot) arms from Universal Robots and Mobile Industrial Robots (MiR), as well as emerging mobile manipulators from companies like Boston Dynamics (Stretch) and newer startups. ROBIN's differentiator is its combination of a mobile base, dual compliant arms, and imitation-learning for task acquisition, aiming for versatility in unstructured environments. The edge rests on the integration of these capabilities into a single, purportedly cost-effective platform. This integration advantage is fragile, however, as it depends on continued software development to make the imitation-learning robust and the fleet management scalable. The company is exposed to competitors with deeper pockets for R&D and, critically, those with established integrator and distributor networks that Roboligent has yet to build.

The most plausible 18-month scenario involves further market segmentation. If Roboligent successfully converts its proof-of-concept projects into paid commercial deployments, particularly in a niche like surface finishing or kitting where its force-control is uniquely valuable, it could secure a beachhead. A winner in this case would be a specialist robotics integrator looking for a flexible, mid-cost manipulation solution. Conversely, if the company cannot demonstrate commercial traction beyond grants and fails to narrow its focus, it becomes a loser in the capital efficiency race. Its modest funding total of approximately $1.11M leaves little room for parallel development across two demanding markets [CB Insights]. The competitive risk is not being out-featured but being outlasted by better-capitalized players who can afford longer sales cycles and more extensive pilot programs.

Data Accuracy: YELLOW -- Competitive positioning inferred from product claims and market segments; no direct competitor names or funding comparisons are publicly cited.

Opportunity

PUBLIC Roboligent's opportunity rests on the premise that its core technology, force-controlled robotics, can unlock a multi-billion dollar wedge across two of the most labor-constrained and automation-hungry sectors: manufacturing and healthcare.

The headline opportunity for Roboligent is to become a category-defining provider of safe, collaborative mobile manipulators, establishing the ROBIN platform as a default solution for tasks requiring dexterity and human proximity. The cited evidence that makes this outcome reachable, rather than purely aspirational, is the company's early, tangible focus on solving specific, high-value problems. Its technology is not a general-purpose humanoid in search of a use case; it is a force-controlled system already being applied to precise physical therapy automation (REGEN) and undergoing proof-of-concept projects for industrial tasks like loading and assembly [Roboligent website, June 2024]. This dual-application foundation suggests a versatile core technology that can be validated in the tightly regulated healthcare environment before scaling into the high-volume industrial market, a common and effective path for advanced robotics.

Growth is likely to follow one of several concrete, named paths. The company's current positioning and partnerships point toward two primary scenarios for achieving scale.

Scenario	What happens	Catalyst	Why it's plausible
Therapeutic Standard-Bearer	REGEN/Optimo Regen becomes a standard piece of equipment in outpatient rehabilitation clinics, automating repetitive therapy exercises and freeing clinicians for higher-value care.	A successful clinical evaluation study and a partnership with a major medical device distributor or rehab network.	The product is described as being on a "solid commercial route" with a collaborator for clinical use [Roboligent website, "REGEN"]. The addressable market of musculoskeletal rehabilitation is vast and faces severe therapist shortages.
Industrial Automation Niche Dominance	The ROBIN platform wins a dominant share in a specific, high-mix, low-volume assembly or finishing niche within advanced manufacturing, where its force control and mobility provide a unique advantage over traditional fixed robots.	Securing a flagship deployment with a known manufacturer in a sector like aerospace or electronics, validated by a public case study.	ROBIN is structured for "precise tasks" and is already in PoC projects in domestic and international settings [Roboligent website, "ROBIN"]. The technology directly addresses the flexibility gap in small-batch production.

Compounding for Roboligent would look like a data and integration flywheel. Each successful deployment of a REGEN unit in a clinic generates proprietary data on human-robot interaction and therapy efficacy, which can be used to refine the AI's imitation-learning algorithms. These improved algorithms then make the industrial ROBIN platform more capable and easier to train for new tasks, lowering the barrier to adoption in factories. Similarly, proving reliability in one industrial niche builds a referenceable track record that reduces perceived risk for adjacent applications, creating a path from surface finishing to advanced assembly to logistics. Early signals of this cross-pollination are visible in the company's description of ROBIN's capabilities, which include "imitation-learning task acquisition" derived from its work on interactive systems [Roboligent website, "ROBIN"].

The size of the win, should either primary scenario play out, is anchored by credible comparables. In healthcare robotics, companies like Hocoma (acquired by DIH International) and Ekso Bionics have established valuations in the hundreds of millions for niche rehabilitation automation. In collaborative industrial robotics, publicly traded Universal Robots (a subsidiary of Teradyne) achieved a multi-billion dollar valuation by dominating the market for small, safe robotic arms. If Roboligent executes on the Therapeutic Standard-Bearer scenario and captures a meaningful portion of the outpatient rehab automation market, an outcome in the high hundreds of millions is plausible (scenario, not a forecast). Success in the Industrial Automation Niche Dominance scenario, given the larger TAM for factory automation, could support a valuation an order of magnitude larger, though it would require capturing a more competitive and fragmented market.

Data Accuracy: YELLOW -- Opportunity scenarios are extrapolated from cited product descriptions and market logic; specific catalyst details (e.g., named clinical study partners) are not publicly confirmed.

Sources

PUBLIC

1. [Roboligent website] Roboligent | Intelligent Manufacturing Automation | https://www.roboligent.com

2. [CB Insights] Roboligent - Products, Competitors, Financials, Employees, Headquarters Locations | https://www.cbinsights.com/company/roboligent

3. [Roboligent website, June 2024] Revolutionizing Robotics: The Future with Roboligent | https://www.roboligent.com/post/revolutionizing-robotics-the-future-with-roboligent

4. [Crunchbase] Bongsu Kim - Founder, CEO @ Roboligent - Crunchbase Person Profile | https://www.crunchbase.com/person/bongsu-kim

5. [Explorium] Explorium company overview for Roboligent | https://www.explorium.ai/manufacturing/companies/roboligent

6. [LinkedIn, retrieved 2026] Roboligent | LinkedIn | https://www.linkedin.com/company/roboligent

7. [Grand View Research, 2024] Grand View Research report on medical robotics market | https://www.grandviewresearch.com/industry-analysis/medical-robotics-market

8. [International Federation of Robotics, 2024] International Federation of Robotics report on collaborative robot shipments | https://ifr.org/ifr-press-releases/news/cobot-market-shows-resilience